Find Hematology Clinical Drug Pipeline Developments & Deals

Lead Product(s): Danicopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

Deal Size: $930.0 million Upfront Cash: $930.0 million

Deal Type: Acquisition January 28, 2020

Details:

Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases.

Lead Product(s): Desidustat

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: China Medical System Holdings Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 20, 2020

Details:

Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.

Lead Product(s): Triferic

Therapeutic Area: Hematology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Sun Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 14, 2020

Details:

Under the terms of the agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic in India and Rockwell Medical will supply the product to Sun Pharma.

Lead Product(s): Avatrombopag

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Enrollment remains ongoing for the phase 3 clinical study of avatrombopag for the treatment of patients with CIT.

Lead Product(s): Nomacopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

All patients treated with nomacopan achieved the primary endpoint of transfusion independence.

Lead Product(s): Eculizumab

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

To date, SB12 (AMT904) is the only biosimilar candidate referencing Soliris® (eculizumab) to be granted IND approval in China.

Lead Product(s): Ferric Maltol

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical

Deal Size: $62.8 million Upfront Cash: $11.4 million

Deal Type: Licensing Agreement January 08, 2020

Details:

Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .

Lead Product(s): APL 2

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

In a head-to-head phase 3 trial after 16 weeks, hemoglobin levels in the pegcetacoplan arm had increased by 3.8 g/dL over the Soliris group, resulting in the trial hitting its primary endpoint.